Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb study of LIB-01 for the treatment of erectile dysfunction

Next Previous
Trial Profile

A phase IIb study of LIB-01 for the treatment of erectile dysfunction

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LIB 01 (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Sponsors Dicot

Most Recent Events

  • 25 Jun 2026 trial event According to a Dicot Pharma media release, an application to initiate phase IIb trial in Europe are underway and company plans to submit it in the third quarter of 2026.
  • 25 Jun 2026 According to Dicot Pharma media release, The FDA now has up to 30 days to raise any questions about the study design. During this period, Dicot Pharma is ready to address potential questions and make necessary adjustments. In parallel, the company is preparing a corresponding application to regulatory authorities in Europe.
  • 25 Jun 2026 According to Dicot Pharma media release, company announces that the company has submitted an IND application (Investigational New Drug Application) to the US Food and Drug Administration, FDA, ahead of the planned phase 2b study of the drug candidate LIB-01, developed for erectile dysfunction.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top